News Summary:
- Waters new LC-MS grade reagents, enzymes, and
software simplify large molecule RNA analysis to accelerate and
improve development of mRNA vaccines, personalized cancer
therapies, and innovative drugs for genetic disorders.
- Novel digestion enzymes deliver complete RNA sequence
coveragei for more confident characterization,
while new LC-MS-grade reagents increase sensitivity and improve
detection accuracy of RNA components.ii
- New waters_connect™ MAP Sequence software accelerates RNA
oligonucleotide mapping using semi-automated workflows that reduce
data processing time over manual techniques, enabling routine
monitoring of key product attributes.
MILFORD,
Mass., Oct. 10, 2024 /PRNewswire/ -- Waters
Corporation (NYSE: WAT) today introduced a comprehensive set
of sample preparation enzymes, reagents, and waters_connect
software that simplify sequence and modification confirmation of
large molecule RNA therapeutics using liquid chromatography-mass
spectrometry (LC-MS) analysis. When used together in a workflow,
these bioseparations tools help accelerate and improve the
development of innovative large molecule RNA-based pharmaceuticals,
such as CRISPR sgRNA and mRNA therapeutics.
Waters new enzymes, reagents, and software
help simplify the confirmation of sequence and modifications of RNA
molecules
Large molecule RNA (ribonucleic acid) therapeutics represent
some of the most exciting and potentially life-saving developments
in pharmaceuticals today. They include new and more effective
vaccines for diseases like COVID-19, personalized cancer
treatments, as well as emerging CRISPR RNA therapies that address
challenging genetic conditions, such as sickle cell anemia.
"As RNA-based therapies are prepared for widespread use, more
direct composition measurements are needed to ensure stability,
safety, and effectiveness for patients," said Erin Chambers, Vice President, Consumables and
Lab Automation at Waters Corporation. "The combination of Waters
enzymes, reagents, and software are specially designed to simplify
the confirmation of sequence and modifications of complex
molecules. These analytical tools can accelerate RNA therapeutic
development and lower barriers for use by LC-MS non-experts."
"As innovators looking to help our customers advance nucleic
acid-based therapies and reduce the burden of serious diseases, we
are always seeking new technologies to improve characterization and
accelerate development," said Arnaud
Delobel, PhD, R&D and Innovation Director at Quality
Assistance S.A. and beta tester of the Waters RNA analytical tools.
"Waters new enzymes efficiently digest mRNA and sgRNA with short
incubation times and data processing in MAP Sequence allows the
user to obtain reproducible results quickly with confidence."
The Waters RNA analytical tools include:
- Enzymes: Two novel enzymes, RapiZyme™ MC1 and
RapiZyme Cusativin, are used in a simplified three-step protocol
that provides complete LC-MS sequence coverage over traditional
digestion methods enabling more confident characterization of RNA
molecules.iii
- Reagents: IonHance™ HFIP, an LC-MS-grade reagent,
is formulated to improve ionization and delivers increased spectral
clarity and detection accuracy of RNA components.
- Software: New MAP Sequence application on the
waters_connect software platform simplifies RNA LC-MS oligo mapping
workflows to accelerate analysis and data processing time over
manual techniques using spreadsheets.
Used together within a workflow, the tools generate an LC-MS
fingerprint to confirm product identity, purity, and efficacy. The
tools improve sequence coverage, LC-MS spectral data quality, and
data interpretation. Supported by the compliance-ready
waters_connect software platform, these tools help transition LC
and LC-MS-based digestion analysis from discovery and development
to release and at-line process analytical testing.
Waters RapiZyme RNAses and IonHance HFIP are now available. The
new MAP Sequence App on waters_connect software will be available
on October 18, 2024.
Additional Resources
- Learn more about the Waters RNA Analytical Tools
- Listen to our webinar "Cracking the Code: Analyzing mRNA and
sgRNA with Advanced Enzymes, Mass Spectrometry, and Informatics on
Oct. 16 at 11:00am ET
- Join Waters at the PharmSci 360 conference for an expert
session on "Oligo Mapping of Large RNA Therapeutics by Novel Enzyme
Specificities" with Dr. Bala
Addepalli, Waters Director, R&D New Modalities Portfolio
on Oct. 21, at 11:00am ET
- Follow and connect with Waters via LinkedIn, Twitter, and
Facebook
About Waters Corporation (www.waters.com)
Waters Corporation (NYSE: WAT), a global leader in
analytical instruments and software, has pioneered chromatography,
mass spectrometry, and thermal analysis innovations serving the
life, materials, food, and environmental sciences for more than 65
years. With approximately 7,500 employees worldwide, Waters
operates directly in 35 countries, including 14 manufacturing
facilities, and with products available in more than 100
countries.
Waters, Rapizyme, IonHance, and waters_connect are trademarks
of Waters Technologies Corporation.
Contact:
Janice Foley
Senior Public Relations Manager, Corporate Communications
Waters Corporation
janice_foley@waters.com
+1.617.823.5555
i 100% RNA sequence coverage achieved for HPRT
sgRNA digested with RapiZyme MC1 and RapiZyme Cusativin compared to
traditional digestion methods such as RNase T1. Waters Application
Note 720008539EN: "Tunable Digestions of RNA Using RapiZyme RNases
to Confirm Sequence and Map Modifications" .
ii IonHance HFIP reagents are certified to
contain less than 100 ppb sodium and less than 100 ppb potassium
content, resulting in reduced adduct formation and improved
sensitivity of RNA detection compared to commercially available
HFIP. Waters Application Note 720008540EN: "Evaluating
IonHance Hexafluoroisopropanol (HFIP) for Enhanced LC-MS
Oligonucleotide Analysis"
iii Waters RapiZyme RNase protocol
simplifies sample preparation with three steps including reagent
preparation, RNA digestion, and heat inactivation without the need
to add chemical denaturants and enzyme inhibitors.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/waters-new-bioseparations-tools-accelerate-and-improve-development-of-rna-based-vaccines-and-therapies-using-lc-ms-analysis-302272290.html
SOURCE Waters Corporation